These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35858545)

  • 41. Widespread correlation of KRAB zinc finger protein binding with brain-developmental gene expression patterns.
    Farmiloe G; Lodewijk GA; Robben SF; van Bree EJ; Jacobs FMJ
    Philos Trans R Soc Lond B Biol Sci; 2020 Mar; 375(1795):20190333. PubMed ID: 32075554
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Kras regulatory elements and exon 4A determine mutation specificity in lung cancer.
    To MD; Wong CE; Karnezis AN; Del Rosario R; Di Lauro R; Balmain A
    Nat Genet; 2008 Oct; 40(10):1240-4. PubMed ID: 18758463
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
    Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
    EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
    [TBL] [Abstract][Full Text] [Related]  

  • 44. SREBP1 regulates mitochondrial metabolism in oncogenic KRAS expressing NSCLC.
    Ruiz CF; Montal ED; Haley JA; Bott AJ; Haley JD
    FASEB J; 2020 Aug; 34(8):10574-10589. PubMed ID: 32568455
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Krüppel-like factor 5 mediates cellular transformation during oncogenic KRAS-induced intestinal tumorigenesis.
    Nandan MO; McConnell BB; Ghaleb AM; Bialkowska AB; Sheng H; Shao J; Babbin BA; Robine S; Yang VW
    Gastroenterology; 2008 Jan; 134(1):120-30. PubMed ID: 18054006
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells.
    Unni AM; Harbourne B; Oh MH; Wild S; Ferrarone JR; Lockwood WW; Varmus H
    Elife; 2018 Nov; 7():. PubMed ID: 30475204
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Profiling oncogenic KRAS mutant drugs with a cell-based Lumit p-ERK immunoassay.
    Swiatnicki M; Engel L; Shrestha R; Alves J; Goueli SA; Zegzouti H
    SLAS Discov; 2022 Jun; 27(4):249-257. PubMed ID: 35288294
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Deregulated lncRNA expression profile in the mouse lung adenocarcinomas with KRAS-G12D mutation and P53 knockout.
    Zhang M; Jiang N; Cui R; Du S; Ou H; Chen T; Ge R; Ma D; Zhang J
    J Cell Mol Med; 2019 Oct; 23(10):6978-6988. PubMed ID: 31410985
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer.
    Kikuchi H; Pino MS; Zeng M; Shirasawa S; Chung DC
    Cancer Res; 2009 Nov; 69(21):8499-506. PubMed ID: 19843849
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients.
    Liu J; Huang X; Liu H; Wei C; Ru H; Qin H; Lai H; Meng Y; Wu G; Xie W; Mo X; Johnson CH; Zhang Y; Tang W
    J Transl Med; 2021 Jan; 19(1):27. PubMed ID: 33413474
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel method, digital genome scanning detects KRAS gene amplification in gastric cancers: involvement of overexpressed wild-type KRAS in downstream signaling and cancer cell growth.
    Mita H; Toyota M; Aoki F; Akashi H; Maruyama R; Sasaki Y; Suzuki H; Idogawa M; Kashima L; Yanagihara K; Fujita M; Hosokawa M; Kusano M; Sabau SV; Tatsumi H; Imai K; Shinomura Y; Tokino T
    BMC Cancer; 2009 Jun; 9():198. PubMed ID: 19545448
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of subsets of actionable genetic alterations in KRAS-mutant lung cancers using association rule mining.
    Tayou J
    Cell Oncol (Dordr); 2018 Aug; 41(4):395-408. PubMed ID: 29679238
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genetic disruption of oncogenic Kras sensitizes lung cancer cells to Fas receptor-mediated apoptosis.
    Mou H; Moore J; Malonia SK; Li Y; Ozata DM; Hough S; Song CQ; Smith JL; Fischer A; Weng Z; Green MR; Xue W
    Proc Natl Acad Sci U S A; 2017 Apr; 114(14):3648-3653. PubMed ID: 28320962
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
    Korzeniecki C; Priefer R
    Eur J Med Chem; 2021 Feb; 211():113006. PubMed ID: 33228976
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transcriptome analyses of tumor-adjacent somatic tissues reveal genes co-expressed with transposable elements.
    Chung N; Jonaid GM; Quinton S; Ross A; Sexton CE; Alberto A; Clymer C; Churchill D; Navarro Leija O; Han MV
    Mob DNA; 2019; 10():39. PubMed ID: 31497073
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
    Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
    Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
    Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
    Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PKC
    Garg R; Cooke M; Benavides F; Abba MC; Cicchini M; Feldser DM; Kazanietz MG
    Cancer Res; 2020 Dec; 80(23):5166-5173. PubMed ID: 32994205
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
    Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
    Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differential Effector Engagement by Oncogenic KRAS.
    Yuan TL; Amzallag A; Bagni R; Yi M; Afghani S; Burgan W; Fer N; Strathern LA; Powell K; Smith B; Waters AM; Drubin D; Thomson T; Liao R; Greninger P; Stein GT; Murchie E; Cortez E; Egan RK; Procter L; Bess M; Cheng KT; Lee CS; Lee LC; Fellmann C; Stephens R; Luo J; Lowe SW; Benes CH; McCormick F
    Cell Rep; 2018 Feb; 22(7):1889-1902. PubMed ID: 29444439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.